odiparcil
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2002 (NCT00041509)
Timeline
Indications
Mechanism of action
- GlycosaminoglycansMODULATOR
Glycosaminoglycans modulator
Replaces D-xylose as a substrate of galactosyltransferase I. The resulting β-D-xyloside-bound GAG is soluble and released into the circulation.
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(=O)oc2cc(O[C@@H]3SC[C@@H](O)[C@H](O)[C@H]3O)ccc12- Mol. weight
- 324.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107763 ↗
Also known as
- odiparcil
- odiparcil
- odiparcil
- sb424323
- sb-424323
- sb-424323
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03370653 | Phase 2 | Dec 13, 2017 | Centro Hospitalar do Porto, Inventiva Pharma, Johannes Gutenburg University, University of London, University of Lyon |
| NCT00437242 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
| NCT00240643 | Phase 2 | Nov 1, 2005 | GlaxoSmithKline |
| NCT00244725 | Phase 2 | Sep 1, 2005 | GlaxoSmithKline |
| NCT00041509 | Phase 2 | Jan 1, 2002 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2002 |
| Centro Hospitalar do Porto | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Inventiva Pharma | For profit | 1 | 1 | 1 | 2017 |
| Johannes Gutenburg University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Lyon | Academic/Hospital | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1